Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jake R Morgan

Showing results (41-50 of 80) with videos related to

Pageof 8
Sort By:
Journal of Substance Abuse Treatment|June 21, 2021
Potential barriers to filling buprenorphine and naltrexone prescriptions among a retrospective cohort of individuals with opioid use disorderJake R Morgan, Emily K Quinn, Christine E Chaisson, et al.
JAMA Network Open|July 12, 2022
Prevalence of HIV Preexposure Prophylaxis Prescribing Among Persons With Commercial Insurance and Likely Injection Drug UseCarl G Streed, Jake R Morgan, Mam Jarra Gai, et al.
American Journal of Obstetrics and Gynecology|May 25, 2022
Buprenorphine uptake during pregnancy following the 2017 guidelines update on prenatal opioid use disorderMax Jordan Nguemeni Tiako, Angelica Meinhofer, Ari Friedman, et al.
Addiction (Abingdon, England)|March 19, 2021
Opioid use disorder and overdose among youth following an initial opioid prescriptionScott E Hadland, Sarah M Bagley, Mam Jarra Gai, et al.
Drug and Alcohol Dependence|May 29, 2021
Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohortJake R Morgan, Alexander Y Walley, Sean M Murphy, et al.
JAMA Health Forum|July 26, 2024
Insurance Instability for Patients With Opioid Use Disorder in the Year After DiagnosisPaul J Christine, Anna L Goldman, Jake R Morgan, et al.
JAMA Health Forum|November 27, 2024
Changes in Postpartum Opioid Prescribing After Implementation of State Opioid Prescribing LimitsCarrie E Fry, Alvin D Jeffery, Manuel Horta, et al.
The International Journal on Drug Policy|May 16, 2019
Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioidsJoshua A Barocas, Jake R Morgan, David A Fiellin, et al.
JAMA Network Open|December 15, 2020
Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient SettingJake R Morgan, Joshua A Barocas, Sean M Murphy, et al.
Medical Care|January 13, 2022
Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan DesignJake R Morgan, Emily K Quinn, Christine E Chaisson, et al.
Pageof 8

Showing results (41-50 of 80) with videos related to

Sort By:
Pageof 8
Journal of Substance Abuse Treatment|June 21, 2021
Potential barriers to filling buprenorphine and naltrexone prescriptions among a retrospective cohort of individuals with opioid use disorderJake R Morgan, Emily K Quinn, Christine E Chaisson, et al.
JAMA Network Open|July 12, 2022
Prevalence of HIV Preexposure Prophylaxis Prescribing Among Persons With Commercial Insurance and Likely Injection Drug UseCarl G Streed, Jake R Morgan, Mam Jarra Gai, et al.
American Journal of Obstetrics and Gynecology|May 25, 2022
Buprenorphine uptake during pregnancy following the 2017 guidelines update on prenatal opioid use disorderMax Jordan Nguemeni Tiako, Angelica Meinhofer, Ari Friedman, et al.
Addiction (Abingdon, England)|March 19, 2021
Opioid use disorder and overdose among youth following an initial opioid prescriptionScott E Hadland, Sarah M Bagley, Mam Jarra Gai, et al.
Drug and Alcohol Dependence|May 29, 2021
Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohortJake R Morgan, Alexander Y Walley, Sean M Murphy, et al.
JAMA Health Forum|July 26, 2024
Insurance Instability for Patients With Opioid Use Disorder in the Year After DiagnosisPaul J Christine, Anna L Goldman, Jake R Morgan, et al.
JAMA Health Forum|November 27, 2024
Changes in Postpartum Opioid Prescribing After Implementation of State Opioid Prescribing LimitsCarrie E Fry, Alvin D Jeffery, Manuel Horta, et al.
The International Journal on Drug Policy|May 16, 2019
Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioidsJoshua A Barocas, Jake R Morgan, David A Fiellin, et al.
JAMA Network Open|December 15, 2020
Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient SettingJake R Morgan, Joshua A Barocas, Sean M Murphy, et al.
Medical Care|January 13, 2022
Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan DesignJake R Morgan, Emily K Quinn, Christine E Chaisson, et al.
Pageof 8